This study is testing a new medicine called AMG 410 for adults with advanced solid tumors that have changes in a gene called KRAS. The goal is to see how safe AMG 410 is and what dose works best. The study has two parts: first, different doses of AMG 410 will be tested alone or with other medicines to find the safest dose; then, more participants will join to see if AMG 410 helps specific types of tumors. In this study, participants will take the medicine by mouth.

• The study can last up to 3 years, but participants can stop if the disease worsens or side effects are too strong.
• Participants must be at least 18 years old and have no other treatment options.
• People with some health conditions, like other cancers or infections, cannot join.

Participants need to provide a sample of their tumor tissue from the past 5 years or might need a biopsy. It's important for participants to be aware of their health and talk to their doctor about joining this study.